▶ TRI-RECEPTOR INCRETIN AGONIST · SUBTOPIC · SAFETY PROFILE
TRI-RECEPTOR INCRETIN AGONIST Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of TRI-RECEPTOR INCRETIN AGONIST.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of TRI-RECEPTOR INCRETIN AGONIST. Severity, frequency, and attribution depend on the source publication.
- Nausea (dose-dependent)
- Vomiting
- Diarrhea
- Constipation
- Injection-site reactions
- Resting heart-rate increase
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for TRI-RECEPTOR INCRETIN AGONIST.
- Other GLP-1R agonists (concurrent use not studied)
- Insulin / sulfonylureas (hypoglycemia risk)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for TRI-RECEPTOR INCRETIN AGONIST in the published record:
- Personal/family history of medullary thyroid carcinoma (class-based caution)
- Multiple endocrine neoplasia type 2
FDA REGULATORY STATUS
Investigational compound · NOT FDA-approved · TRIUMPH Phase 3 program ongoing as of 2026-05.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ What is the triple-receptor incretin agonist?
the triple-receptor incretin agonist (the originator pharma sponsor code its development codename) is a synthetic peptide engineered as a triple agonist at the GLP-1, GIP, and glucagon receptors. It is an investigational compound · not FDA-approved · currently in the Phase 3 TRIUMPH program.
▶ Is the triple-receptor incretin agonist FDA-approved?
No. the triple-receptor incretin agonist is an investigational compound. The Phase 3 TRIUMPH program is ongoing. The substance sold here is supplied as a research-grade reference compound for in-vitro use only.
▶ Is the triple-receptor incretin agonist banned by WADA?
the triple-receptor incretin agonist is not currently listed on the WADA Prohibited List as of the 2026 update. Status can change · always verify with the current WADA list before competition.
▶ What were the most common side effects in Phase 2?
Gastrointestinal events (nausea, vomiting, diarrhea) were the dominant adverse-event class, dose-dependent and mostly mild-to-moderate. Dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter.
▶ the triple-receptor incretin agonist vs the FDA-approved class member / the long-acting GLP-1 agonist · what's different?
the long-acting GLP-1 agonist (the FDA-approved class member, the FDA-approved class member) is a GLP-1 receptor agonist only. the triple-receptor incretin agonist is a triple agonist at GLP-1, GIP and the glucagon receptor. The added GIP arm increases absolute weight loss over the long-acting GLP-1 agonist at comparable timepoints. The added glucagon arm drives thermogenic / energy-expenditure signaling that the long-acting GLP-1 agonist does not produce. Published Phase 2 the triple-receptor incretin agonist reached -24.2% body weight at 48 weeks vs the published STEP-1 the long-acting GLP-1 agonist 2.4 mg result of -14.9% at 68 weeks.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist the triple-receptor incretin agonist for Obesity · A Phase 2 Trial. N Engl J Med 2023. PMID 37366315. link
- the originator pharma sponsor and Company. A Study of its development codename in Participants With Obesity (Phase 2). ClinicalTrials.gov 2021. NCT04881760. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19